On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Review uri icon

Overview

abstract

  • The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.

publication date

  • March 25, 2015

Research

keywords

  • Immune Tolerance
  • Lymphocyte Activation
  • Neoplasms
  • T-Lymphocytes

Identity

Scopus Document Identifier

  • 84925625990

Digital Object Identifier (DOI)

  • 10.1126/scitranslmed.3010274

PubMed ID

  • 25810313

Additional Document Info

volume

  • 7

issue

  • 280